Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GLS | O94925 | 5/20 | 0.56 |
| ▸ | GRK6 | P43250 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21368698 | 0.87 | HTT (0.63) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL17221747 | 0.86 | HDAC1 (0.61) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL14256403 | 0.85 | HTT (0.68) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL14987117 | 0.81 | HTT (0.63) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL14987037 | 0.80 | GLS (0.69) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL15081591 | 0.80 | HTT (0.61) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL13933220 | 0.79 | HTT (0.60) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL19920010 | 0.78 | HTT (0.60) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL29809114 | 0.78 | HTT (0.59) | HTTTSHRKMT2AMEN1GLS | |
| SCHEMBL110733 | 0.78 | HTT (0.59) | HTTTSHRKMT2AMEN1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | SYNHALE THERAPEUTICS INC. | 2017-12-28 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-8865718-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 547/4885TSHR 3721/4885KMT2A 533/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | HTT 301/4885TSHR 3065/4885KMT2A 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.